Close Menu

Breaking News

Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.

Last week, GenomeWeb readers were most interested in a report of cases where genetic testing was incorrectly recommended, ordered, interpreted, or used.

The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.

The clinic will offer comprehensive DNA sequencing, interpretation, and reporting of disease-associated genes for healthy adults and their children.

The award will go to Jocelyn Silvester of Children's Hospital Boston, to fund transcriptomics research on intestinal inflammation caused by gluten.

The FDA has granted accelerated approval to Rozlytrek as a treatment for adult and adolescent patients with NTRK fusion-positive cancers.

The $10 million initiative will include scientists from the University of California's campuses, as well as from governmental and nongovernmental organizations.

Industry players, faced with vague communications from the agency, scramble to decipher regulatory expectations and criticize the agency for trying to control PGx knowledge.

The researchers identified genes that specifically extend the lifespan of neurons and found genes that increase the number of neurites in the brain.

The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.

The team saw risky mutations in colorectal cancer, polyp, and Lynch syndrome-related genes in almost 4 percent of CRC patients diagnosed at 72 years old, on average.

In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.

The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.

The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.

The firms announced a deal to develop services and products for sequencing-based T cell and B cell receptor profiling in the US and Europe.

By analyzing metagenomic sequences found in thousands of human mouth and gut samples, researchers tracked down almost 45.7 million distinct microbial genes.

The revenue growth was driven in part by sales generated by Australian reagent maker TGR Biosciences, which Expedeon acquired in May last year.

The FDA center of excellence has engaged the technology vendor to incorporate real-world evidence into regulatory decision-making for precision oncology treatments.

The firm reported total revenues of $215.4 million, up from $193.9 million in fiscal Q4 2018, but below the consensus Wall Street estimate of $221.0 million.

In its first quarter operating as a public company, the Seattle-based immune sequencing firm more than tripled development revenues and grew sequencing revenues.

The firm brought in $15.8 million during the quarter compared to $8.8 million a year ago, and beating Wall Street expectations.

The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.